MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
40.40
+0.51
+1.28%
Opening 13:28 08/11 EDT
OPEN
39.66
PREV CLOSE
39.89
HIGH
40.50
LOW
38.99
VOLUME
630.34K
TURNOVER
--
52 WEEK HIGH
41.23
52 WEEK LOW
14.32
MARKET CAP
8.34B
P/E (TTM)
-14.3757
1D
5D
1M
3M
1Y
5Y
1D
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanks · 1d ago
Immunovant price target raised to $45 from $43 at BofA
TipRanks · 1d ago
Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanks · 1d ago
Weekly Report: what happened at IMVT last week (0803-0807)?
Weekly Report · 1d ago
Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained
TipRanks · 4d ago
Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)
TipRanks · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
TipRanks · 4d ago
Immunovant GAAP EPS of -$0.75 misses by $0.12
Seeking Alpha · 5d ago
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.